Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
Shannon Elf, Nouran S. Abdelfattah, Edwin Chen, et al.
Cancer Discovery (2016) Vol. 6, Iss. 4, pp. 368-381
Open Access | Times Cited: 247

Showing 1-25 of 247 citing articles:

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker, Róbert Královics
Blood (2016) Vol. 129, Iss. 6, pp. 667-679
Open Access | Times Cited: 531
Calreticulin and cancer
Jitka Fučíková, Radek Špíšek, Guido Kroemer, et al.
Cell Research (2020) Vol. 31, Iss. 1, pp. 5-16
Open Access | Times Cited: 281
Somatic mutations and cell identity linked by Genotyping of Transcriptomes
Anna S. Nam, Kyu-Tae Kim, Ronan Chaligné, et al.
Nature (2019) Vol. 571, Iss. 7765, pp. 355-360
Open Access | Times Cited: 263
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 214
The regulation of JAKs in cytokine signaling and its breakdown in disease
Henrik M. Hammarén, Anniina Virtanen, Juuli Raivola, et al.
Cytokine (2018) Vol. 118, pp. 48-63
Open Access | Times Cited: 186
Myeloproliferative neoplasm stem cells
Adam J. Mead, Ann Mullally
Blood (2017) Vol. 129, Iss. 12, pp. 1607-1616
Open Access | Times Cited: 158
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
William Vainchenker, Emilie Leroy, Laure Gilles, et al.
F1000Research (2018) Vol. 7, pp. 82-82
Open Access | Times Cited: 142
Myeloproliferative neoplasms: from origins to outcomes
Jyoti Nangalia, Anthony R. Green
Blood (2017) Vol. 130, Iss. 23, pp. 2475-2483
Open Access | Times Cited: 127
Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
Daniel A.C. Fisher, Cathrine A. Miner, Elizabeth K. Engle, et al.
Leukemia (2019) Vol. 33, Iss. 8, pp. 1978-1995
Open Access | Times Cited: 124
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Prithviraj Bose, Srđan Verstovšek
Blood (2017) Vol. 130, Iss. 2, pp. 115-125
Open Access | Times Cited: 99
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms
Simona Stivala, Tamara Codilupi, Šime Brkić, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 4, pp. 1596-1611
Open Access | Times Cited: 97
Immunosuppression by Mutated Calreticulin Released from Malignant Cells
Peng Liu, Liwei Zhao, Friedemann Loos, et al.
Molecular Cell (2019) Vol. 77, Iss. 4, pp. 748-760.e9
Open Access | Times Cited: 96
Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms
Jacob Grinfeld, Jyoti Nangalia, Anthony R. Green
Haematologica (2016) Vol. 102, Iss. 1, pp. 7-17
Open Access | Times Cited: 90
Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia
D. Fisher, Olga Malkova, Elizabeth K. Engle, et al.
Leukemia (2016) Vol. 31, Iss. 9, pp. 1962-1974
Open Access | Times Cited: 89
Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants
C. Pecquet, Ilyas Chachoua, Anita Roy, et al.
Blood (2019) Vol. 133, Iss. 25, pp. 2669-2681
Open Access | Times Cited: 84
Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms
Cansu Cimen Bozkus, Vladimir Roudko, John P. Finnigan, et al.
Cancer Discovery (2019) Vol. 9, Iss. 9, pp. 1192-1207
Open Access | Times Cited: 83
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Daniel Arthur Corpuz Fisher, Jared S. Fowles, Amy Zhou, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 82
JAK inhibitors and COVID-19
Gabriel Levy, Paola Guglielmelli, Peter Langmuir, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 4, pp. e002838-e002838
Open Access | Times Cited: 52
Biology and therapeutic targeting of molecular mechanisms in MPNs
Joan How, Jacqueline S. Garcia, Ann Mullally
Blood (2022) Vol. 141, Iss. 16, pp. 1922-1933
Open Access | Times Cited: 39
Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage
Juan Li, Daniel Prins, Hyun Jung Park, et al.
Blood (2017) Vol. 131, Iss. 6, pp. 649-661
Open Access | Times Cited: 85
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN
Shannon Elf, Nouran S. Abdelfattah, April J. Baral, et al.
Blood (2017) Vol. 131, Iss. 7, pp. 782-786
Open Access | Times Cited: 84
Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
Lijuan Han, Claudia Schubert, Johanna Köhler, et al.
Journal of Hematology & Oncology (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 83
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
Kotaro Shide, Takuro Kameda, Takumi Yamaji, et al.
Leukemia (2016) Vol. 31, Iss. 5, pp. 1136-1144
Open Access | Times Cited: 70
The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin
Leila N. Varghese, Jean‐Philippe Defour, C. Pecquet, et al.
Frontiers in Endocrinology (2017) Vol. 8
Open Access | Times Cited: 70
Myelofibrosis biology and contemporary management
Naseema Gangat, Ayalew Tefferi
British Journal of Haematology (2020) Vol. 191, Iss. 2, pp. 152-170
Open Access | Times Cited: 70
Page 1 - Next Page

Scroll to top